Home › Therapeutic areas › Oncology › Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer (40 companies)
Companies with an active program in Non-Small Cell Lung Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $61.4M | 9 |
| AKTS | Aktis Oncology | Oncology | 2 | Phase 1 | $910M | 10 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | $2.36B | 8 |
| AVBP | ArriVent BioPharma | Oncology | 1 | Phase 3 | $553M | 7 |
| BDTX | Black Diamond Therapeutics | Oncology | 2 | Phase 2 | $82.8M | 4 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 2 | Phase 1 | $156M | 6 |
| CCCC | C4 Therapeutics | Oncology | 1 | Phase 2 | $332M | 2 |
| CADL | Candel Therapeutics | Oncology | 1 | Phase 3 | $424M | 4 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $109M | 15 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | $191M | 7 |
| CBIO | Crescent Biopharma | Oncology | 1 | Phase 2 | $507M | 10 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $602M | 10 |
| EIKN | Eikon Therapeutics | Oncology | 1 | Phase 2 | $279M | 13 |
| ERAS | Erasca | Oncology | 1 | Phase 1 | $4.87B | 5 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | $16.7B | 23 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $96.1M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $2.65B | 15 |
| IMTX | Immatics | Oncology | 2 | Phase 3 | $958M | 8 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $224M | 5 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $6.66B | 17 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 1 | Approved | $1.44B | 12 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.03B | 9 |
| INBX | Inhibrx Biosciences | Oncology | 1 | NDA Submitted | $1.10B | 6 |
| KAPA | Kairos Pharma | Oncology | 2 | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 1 | Phase 2 | $60.7M | 13 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $688M | 13 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $77.2M | 8 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.23B | 11 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | $95.4M | 7 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 2 | Phase 3 | $660M | 9 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $831M | 5 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | $92.2M | 7 |
| RVMD | Revolution Medicines | Oncology | 3 | Approved | $35.2B | 11 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $8.53B | 6 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 1 | Approved | $822M | 7 |
| TNGX | Tango Therapeutics | Oncology | 3 | Phase 1 | $3.75B | 5 |
| VSTM | Verastem | Oncology | 1 | Approved | $934M | 5 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.59B | 28 |
| ZYME | Zymeworks | OncologyRespiratory | 2 | Approved | $1.78B | 12 |
No companies match.